SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001328143-21-000007
Filing Date
2021-02-01
Accepted
2021-02-01 08:05:22
Documents
14
Period of Report
2021-01-30
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K adms-20210130.htm   iXBRL 8-K 33868
  Complete submission text file 0001328143-21-000007.txt   181391

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adms-20210130.xsd EX-101.SCH 2423
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT adms-20210130_cal.xml EX-101.CAL 710
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT adms-20210130_def.xml EX-101.DEF 1643
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adms-20210130_lab.xml EX-101.LAB 26042
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adms-20210130_pre.xml EX-101.PRE 14071
7 EXTRACTED XBRL INSTANCE DOCUMENT adms-20210130_htm.xml XML 10978
Mailing Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

IRS No.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36399 | Film No.: 21574408
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences